Evidence map›Paper›PMID 40140526›Full record

ArticleActa pharmacologica Sinica2025

Huperzine A attenuates epileptic seizures via enhancing dCA1-projecting septal cholinergic transmission.

Yu Wang, Ke-Yu Hu, Qing-Yang Zhang, Ying-Jie Song, Ling-Jie Li, Fei Wang, Gang Tian, Fan Fei, Ceng-Lin Xu, Jia-Jia Fang and 5 more

Abstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yu Wang *Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Ke-Yu Hu *Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Qing-Yang Zhang *Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Ying-Jie Song *Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Ling-Jie LiZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Fei WangZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Gang TianZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Fan FeiZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Ceng-Lin XuZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Jia-Jia FangInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences & The Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China.
Xu-Hong JiangZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Jian-Nong WuZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Wen-Lu LiZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Yi WangZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China. wang-yi@zju.edu.cn.ORCID http://orcid.org/0000-0002-1350-2961
Zhong ChenZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences & The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China. chenzhong@zju.edu.cn.ORCID http://orcid.org/0000-0003-4755-9357

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholinergic transmission, independent of classical glutamatergic and GABAergic signaling, critically plays a crucial role in epilepsy. Huperzine A (Hup A), an acetylcholinesterase (AChE) inhibitor, exerts potent anticonvulsant activity, but its mechanism of action within cholinergic circuits remains unclear. Here, we show that Hup A mitigates epileptic seizures by enhancing hippocampal dorsal CA1 (dCA1)-projecting cholinergic transmission. We found that systemic injection of Hup A not only reduces seizures in acute models, including the maximal-electroshock seizure (MES), pentylenetetrazol (PTZ), and kainic acid (KA) models but also alleviates the seizure severity in chronic epilepsy models induced by kindling and KA, indicating a broad-spectrum anti-seizure efficacy. Interestingly, using immunohistochemistry, viral tracing, and in vivo fiber photometry, we found that Hup A selectively inhibits AChE in the dCA1 rather than in other hippocampal subregions or cortex, enhancing dCA1-projecting septal cholinergic transmission. Significantly, selective ablation of septal ChAT

Indexed as

AlkaloidsAnticonvulsantsCA1 Region, HippocampalCholinesterase InhibitorsEpilepsySeizuresSesquiterpenesAcetylcholinesterasealpha7 Nicotinic Acetylcholine ReceptorAnimalsDisease Models, AnimalKainic AcidMaleMiceMice, Inbred C57BLSynaptic TransmissionAcetylcholinesteraseAlkaloidsalpha7 Nicotinic Acetylcholine ReceptorAnticonvulsantsCholinesterase Inhibitorshuperzine AKainic AcidSesquiterpenescholinergic circuitepilepsyhippocampal dorsal CA1 regionhuperzine Aα7 nicotinic acetylcholine receptor

Identifiers

PMID40140526
PMCPMC12274539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.